PeopleThomas Engelen
Thomas Engelen
Thomas EngelenNon-executive DirectorThomas Engelen has a track record in creating value in listed and in Private Equity backed investments in Life Sciences and Chemicals including financial and operational turn-around as part of MBOs and MBIs.Engelen is co-founder of Pneumagen. As non-exec chair Engelen was part of the team in the successful IPO of GT Biologics Ltd to become 4D Pharma Plc, and of Quantum Specials Ltd to become Quantum Pharma Plc, and remained after the IPOs on their board as non-executive director.Previous non-executive chair roles were with Akros Chemicals Ltd, Colonis Pharma Ltd, Martindale Pharma Ltd and Stan Chem International Ltd.Prior to this Engelen worked for Akzo Nobel Pharma in the USA, Brazil, the UK and the Middle East for 19 years in Regional line- and Global HQ management roles.Current engagements include non – exec chair at TMC Pharma Services Ltd, a global pharmaceutical development organisation specialised in Rare and Orphan diseases, Omideon Ltd, and Innovatrain AG, Switzerland.
active0
Roles
team_memberboard_chairfounder
Timeline
Current Company
